These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12405200)

  • 21. HIV-specific T lymphocyte immunity in mice immunized with a recombinant vaccinia virus.
    Michel F; Hoffenbach A; Langlade-Demoyen P; Guy B; Girard M; Lecocq JP; Wain-Hobson S; Kieny MP; Plata F
    Eur J Immunol; 1988 Dec; 18(12):1917-24. PubMed ID: 2905993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
    Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
    J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV/AIDS vaccines: 2007.
    Robinson HL
    Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Chibbar R; Wei Y; Liu Q; Xiang J
    Vaccine; 2011 Apr; 29(19):3538-47. PubMed ID: 21406265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral CD4 and CD8 T-cell memory: differences in the size of the response and activation requirements.
    Whitmire JK; Murali-Krishna K; Altman J; Ahmed R
    Philos Trans R Soc Lond B Biol Sci; 2000 Mar; 355(1395):373-9. PubMed ID: 10794058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of cytokines in the development and maintenance of memory T cells during respiratory viral infection.
    Tripp RA
    Curr Pharm Des; 2003; 9(1):51-9. PubMed ID: 12570674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effector and memory T-cell differentiation: implications for vaccine development.
    Kaech SM; Wherry EJ; Ahmed R
    Nat Rev Immunol; 2002 Apr; 2(4):251-62. PubMed ID: 12001996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-viral protective capacity of tissue resident memory T cells.
    Paik DH; Farber DL
    Curr Opin Virol; 2021 Feb; 46():20-26. PubMed ID: 33130326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memories that last forever: strategies for optimizing vaccine T-cell memory.
    Ahlers JD; Belyakov IM
    Blood; 2010 Mar; 115(9):1678-89. PubMed ID: 19903895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus-specific CD8 T cells: activation, differentiation and memory formation.
    Wiesel M; Walton S; Richter K; Oxenius A
    APMIS; 2009 May; 117(5-6):356-81. PubMed ID: 19400862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel peptide-based vaccines efficiently prime murine "help"-independent CD8+ T cell responses in the liver.
    Dikopoulos N; Riedl P; Schirmbeck R; Reimann J
    Hepatology; 2004 Aug; 40(2):300-9. PubMed ID: 15368434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses.
    Baz A; Buttigieg K; Zeng W; Rizkalla M; Jackson DC; Groves P; Kelso A
    Vaccine; 2008 May; 26(21):2570-9. PubMed ID: 18420312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design.
    Yewdell JW; Haeryfar SM
    Annu Rev Immunol; 2005; 23():651-82. PubMed ID: 15771583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Not-so-great expectations: re-assessing the essence of T-cell memory.
    Intlekofer AM; Wherry EJ; Reiner SL
    Immunol Rev; 2006 Jun; 211():203-13. PubMed ID: 16824129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine.
    Lauvau G; Vijh S; Kong P; Horng T; Kerksiek K; Serbina N; Tuma RA; Pamer EG
    Science; 2001 Nov; 294(5547):1735-9. PubMed ID: 11721060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
    Jackson RJ; Worley M; Trivedi S; Ranasinghe C
    Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing CD8 T cell number and dysfunction in the presence of antigen.
    Welsh RM
    J Exp Med; 2001 Mar; 193(5):F19-22. PubMed ID: 11238597
    [No Abstract]   [Full Text] [Related]  

  • 40. T cells and viral persistence: lessons from diverse infections.
    Klenerman P; Hill A
    Nat Immunol; 2005 Sep; 6(9):873-9. PubMed ID: 16116467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.